The future of one of President Joe Biden's key domestic policy achievements — getting Medicare to negotiate drug prices — could either become part of the Biden administration's legacy, get rolled back by the incoming Congress or be weakened by President-elect Donald Trump's administration. Trump has remained relatively mum about the drug pricing provisions of the 2022 reconciliation bill and its future appears even murkier now that Republicans will control both the House and Senate. "The Trump campaign articulated no position on drug price negotiation specifically, but congressional Republicans are not fans of this program and introduced legislation to repeal the IRA in its entirety," said Juliette Cubanski, deputy director of the program on Medicare policy at KFF.
